McKesson Corporation (MCK) is a publicly traded Healthcare sector company. As of May 20, 2026, MCK trades at $757.50 with a market cap of $93.27B and a P/E ratio of 19.54. MCK moved -0.96% today. Year to date, MCK is -8.51%; over the trailing twelve months it is +4.93%. Its 52-week range spans $479.15 to $999.00. Analyst consensus is strong buy with an average price target of $946.91. Rallies surfaces MCK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
McKesson Sees 2027 Profit Surpass Estimates on Oncology, Specialty Drug Strength: McKesson forecast 2027 profit slightly above consensus after beating Q1 profit estimates, driven by strength in oncology and specialty drug distribution. The company cited robust GLP-1 and biopharma services demand offset by soft medical-surgical trends.
| Metric | Value |
|---|---|
| Price | $757.50 |
| Market Cap | $93.27B |
| P/E Ratio | 19.54 |
| EPS | $38.55 |
| Dividend Yield | 0.82% |
| 52-Week High | $999.00 |
| 52-Week Low | $479.15 |
| Volume | 780.29K |
| Avg Volume | 0 |
| Revenue (TTM) | $403.43B |
| Net Income | $5.10B |
| Gross Margin | 3.61% |
12 analysts cover MCK: 0 strong buy, 11 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $946.91.